In another setting, namely a breast cancer xenograft model, the efficacy of erastin, an inhibitor of xCT cystine/glutamate transporter, was improved when administered during the light phase when compared to the dark phase [114]. This evidence concerns the gene SLC7A11 and breast cancer.